Pharmacological mechanism and clinical target analysis of mobosetinib (Anvili)

Mobocertinib is an oral tyrosine kinase inhibitor (TKI) that mainly targets EGFR gene exon 20 insertion mutation (EGFR exon 20 insertion mutation) patients with non-small cell lung cancer (NSCLC). Traditional EGFR-TKIs (such as gefitinib, erlotinib, and osimertinib) have limited efficacy against this type of mutation. However, through structural optimization, moboxetinib can better bind to the mutated EGFR receptor, inhibit abnormal signaling pathways, and thereby prevent the proliferation and survival of tumor cells.

From a pharmacological mechanism, mobosetinib can selectively and irreversibly inhibit the tyrosine kinase activity of EGFR exon 20 insertion mutation, and also has a certain inhibitory effect on wild-type EGFR. The main pathways it inhibits include the EGFR/ERBB family signaling pathway, blocking the downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling axis, thereby inducing tumor cell apoptosis and inhibiting cell division. This targeted design improves the inhibitory effect on specific mutations and is significantly better than traditional TKIs.

In clinical application, Mobocertinib is specifically used to treat EGFR exon20 insertion mutation-positive metastatic NSCLC whose disease has progressed despite previous platinum-based chemotherapy. Clinical trial data show that the objective response rate (ORR) and progression-free survival (PFS) of mobosetinib have been significantly improved in this population, providing a new option for this type of patients who lack effective treatments. At the same time, due to its molecular structure characteristics, Mobocertinib has relatively weak activity against other common EGFR mutations (such as L858R, 19 exon deletion), showing a high degree of target specificity.

However, since Mobocertinib also acts on some wild-type EGFR, patients may experience side effects such as diarrhea, rash, nausea and QT interval prolongation during treatment. Therefore, ECG and electrolyte monitoring are clinically warranted, and dosage adjustments are made based on tolerability. Overall, the development and application of mobosetinib has filled the treatment gap for patients with EGFR exon20 insertion mutations, and is of great significance in the fields of precision medicine and targeted therapy.

Reference link:https://www.drugs.com